{"id":49867,"date":"2025-11-30T06:36:19","date_gmt":"2025-11-30T05:36:19","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/11\/30\/il-1-family-members-as-regulators-of-lymphoid-type-2-immunity-in-cancer-stefania-roma\/"},"modified":"2025-11-30T06:36:19","modified_gmt":"2025-11-30T05:36:19","slug":"il-1-family-members-as-regulators-of-lymphoid-type-2-immunity-in-cancer-stefania-roma","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/11\/30\/il-1-family-members-as-regulators-of-lymphoid-type-2-immunity-in-cancer-stefania-roma\/","title":{"rendered":"IL-1 family members as regulators of lymphoid type-2 immunity in cancer. Stefania Roma"},"content":{"rendered":"<div>\n<p><b>Semin Immunol<\/b>. 2025 Nov 28;81:102005. doi: 10.1016\/j.smim.2025.102005. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>IL-1 family members, such as IL-1 and IL-33, are present in the tumor microenvironment and exert tumor-intrinsic and tumor-extrinsic functions with both pro- and anti-tumor effects. Among their immunoregulatory roles, both cytokines contribute to lymphoid type-2 immunity. IL-1 can indirectly promote CD4<sup>+<\/sup> Th2 responses by inducing thymic stromal lymphopoietin production by tumor cells or cancer associated fibroblasts that conditions Th2-polarizing dendritic cells, whereas IL-33 is a potent direct activator of CD4<sup>+<\/sup> Th2 and other type-2 immune cells, such as group 2 innate lymphoid cells (ILC2s). In a large majority of established human cancers, CD4<sup>+<\/sup> Th2 cell responses correlate with tumor-promotion, whereas expansion of ILC2s can either suppress or promote tumor immunity in a more balanced way, leading to tumor progression or regression. Interestingly, the two prototypical Th2 cytokines IL-13 and IL-5 exert apparently pro- and anti-tumor opposing functions by recruitment of myeloid-derived cells and eosinophils, respectively. In addition, anti-tumor ILC2s under the influence of the tumor microenvironment may become dysfunctional, ultimately resulting in tumor-progression. Understanding the specific cancer context and considering the similarities as well as the distinctive features of the two lymphoid type-2 cell subsets is essential for developing effective immunotherapeutic strategies by targeting the IL-1 and IL-33 cytokines.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41317636\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=9009458&amp;ff=20251130003618&amp;v=2.18.0.post22+67771e2\">41317636<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1016\/j.smim.2025.102005\">10.1016\/j.smim.2025.102005<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Semin Immunol. 2025 Nov 28;81:102005. doi: 10.1016\/j.smim.2025.102005. Online ahead of print. ABSTRACT IL-1 family members, such as IL-1 and IL-33, are present in the tumor microenvironment and exert tumor-intrinsic and tumor-extrinsic functions with both pro- and anti-tumor effects. Among their immunoregulatory roles, both cytokines contribute to lymphoid type-2 immunity. IL-1 can indirectly promote CD4+ Th2 &#8230; <a title=\"IL-1 family members as regulators of lymphoid type-2 immunity in cancer. Stefania Roma\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/30\/il-1-family-members-as-regulators-of-lymphoid-type-2-immunity-in-cancer-stefania-roma\/\" aria-label=\"Read more about IL-1 family members as regulators of lymphoid type-2 immunity in cancer. Stefania Roma\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,110],"tags":[],"class_list":["post-49867","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-seminars-in-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/49867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=49867"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/49867\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=49867"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=49867"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=49867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}